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Although survival outcomes have improved over the last decade for patients with multiple myeloma
(MM), few patients remain free of disease and most inevitably relapse. Selecting a treatment for patients
with relapsed MM is challenging given the number and diversity of regimens patients may have
previously received, which can affect subsequent therapeutic choices. Importantly, a number of
patient- and disease-related factors can also have an effect on treatment choice, treatment efﬁcacy,
and tolerability; thus, an understanding of the heterogeneity of patients in the setting of relapsed MM
is important for appropriate treatment selection. Here, we review select patient and disease characteris-
tics reported in key interventional and observational studies in relapsed MM (including age, sex, race, and
the presence of high-risk disease, renal impairment, or peripheral neuropathy at baseline) to examine
common and disparate features of patients with relapsed MM. As therapeutic regimens can have varying
efﬁcacy and/or tolerability in patients depending on these factors, we also provide treatment recommen-
dations for patients with select baseline characteristics.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Multiple myeloma (MM) is a common hematologic malignancy,
with an estimated 24,050 new cases (13,500 in men and 10,550 in
women) diagnosed in the United States in 2014, leading to
approximately 11,090 deaths [1]. Survival prospects in MM have
improved during the last decade [2] with the introduction of new
drug regimens, including immunomodulatory drugs (IMiDs; such
as lenalidomide, thalidomide, and pomalidomide), proteasome
inhibitors (such as bortezomib and carﬁlzomib), and pegylated
liposomal doxorubicin. However, despite these modern therapeutic
advances, most patients relapse [3,4].
Precise deﬁnitions of ‘‘relapsed’’ and ‘‘refractory’’ MM may
differ across studies. Among patients who have already received
initial treatment for MM, the term ‘‘relapsed’’ typically refers to
cases where the malignancy recurs after a remission or to patientswho respond to salvage therapy but go on to experience disease
progression while they are being followed with or without mainte-
nance treatment. In contrast, patients with ‘‘refractory’’ MM are
typically those who fail to respond (or have limited response) to
salvage therapy or who progress within 60 days of their last regi-
men [5,6].
Selecting treatment for patients with relapsed MM is a clinical
challenge that requires careful consideration of the balance
between maximizing efﬁcacy and ensuring acceptable tolerability.
Patients who experience only a biochemical relapse (in which dis-
ease progression, as deﬁned by aP25% increase in serum or urine
M-protein, is asymptomatic [7]) may be followed closely without
treatment. However, patients with high-risk disease (e.g. patients
with unfavorable cytogenetics, suboptimal response to prior treat-
ment or aggressive disease at diagnosis [8]), or who demonstrate a
rapid increase in serum or urine M-protein levels (e.g. a doubling
time of 2 months or less), should receive immediate treatment [9].
This review article examines the disease characteristics and
demographics of patients with relapsed MM, focusing predomi-
nantly on those who have relapsed early in their treatment course
(i.e. after 1–3 prior lines of treatment) and who were enrolled in
phase II or III interventional trials or observational studies. This
topic is of particular interest in the era of novel therapeutics, as a
number of patient- and disease-related factors may affect
treatment efﬁcacy and/or tolerability, such as age, sex, race,
baseline organ function, and comorbidities, performance status,
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System (ISS) MM stage, b2-microglobulin level, and the degree of
bone marrow involvement. It should be noted that while most
demographic data speciﬁcally for patients with relapsed MM is
found in the setting of clinical trials, patients enrolled in clinical
trials are likely to be more uniform than those in the population
seen in clinical practice, as they are carefully selected using
predeﬁned inclusion and exclusion criteria. However, keeping
these caveats in mind, understanding the heterogeneity of relapsed
MM patients may also provide opportunities for the personaliza-
tion of treatment, and we have provided treatment recommenda-
tions for patients with select baseline characteristics.Select baseline patient and disease characteristics
Age/frailty
Patient age is a signiﬁcant prognostic factor for patients with
MM, with patients who areP50 years of age at diagnosis display-
ing signiﬁcantly shorter median survival times than younger
patients [10]. While new treatment options have improved
survival, these beneﬁts were largely conﬁned to the subset of
patients aged <70 years [11,12], and it is only recently that survival
advantages have also become evident in older patients [13].
Since older patients typically present with multiple comorbidi-
ties and treatment-related toxicities at relapse, patient populations
with relapsed MM in clinical trials, which are screened with select
inclusion and exclusion criteria, may largely skew toward younger
and ﬁtter patients. While the median age of patients with MM at
diagnosis is 70 years at diagnosis [14], the median patient age
in interventional clinical trials in relapsed MM is frequently around
60–65 years [6,15–34], and the median time since diagnosis for
these patients typically ranges from 2 to 4 years (Table 1) [6,16,1
8–26,28,29,33,34]. Observational studies following patients with
at least one prior relapse have reported slightly higher median ages
(66–69 years) [16,35], with similar median times since diagnosis
(about 3–4 years) [16] compared with patients enrolled in inter-
ventional clinical trials (Table 2).
Even among patients within the same age group, physical and
cognitive functions can vary widely. Measures of performance sta-
tus, such as the Eastern Cooperative Oncology Group (ECOG) scale,
are simple assessments of disability and have been reported to pre-
dict poor prognoses [36]. Clinical trials in MM typically exclude
patients with ECOG performance status greater than 2. In the trials
of patients with relapsed MM summarized in Table 1, the propor-
tion with an ECOG performance status of 1 or 2 ranged from 34% to
61% [6,21–23,25,27–30,33,34,37,38].
Frailty indices speciﬁcally designed to include elderly patients
have also been developed to assess the biological age of patients
in conjunction with their chronological age in order to guide treat-
ment decisions [39–41]. While frailty has been found to be a signif-
icant prognostic factor for patients with MM [41] and these
assessments are gaining in usage, they have not yet been routinely
implemented in clinical trials in the relapsed setting.Treatment recommendations
In elderly patients with relapsed myeloma, a geriatric assess-
ment should be performed. Patients who are ﬁt (e.g. active patients
who do not require assistance for household tasks) should receive
treatments at doses and intervals similar to that of younger
patients. Patients who are unﬁt (e.g. those who can perform lim-
ited activities) should be treated with reduced doses and longer
intervals. For frail patients (e.g. patients who need help from others
for household tasks or personal care), supportive care with orwithout attenuated anti-myeloma therapy should be considered
[3,8,42,43].
Sex
MM occurs at a slightly higher incidence rate in males com-
pared with females (7.7 new cases per 100,000 males vs. 4.9 new
cases per 100,000 females in the United States) [14], and this is
reﬂected in the enrollment proﬁle of interventional and observa-
tional studies, where males make up more than half of patients
enrolled (trials have reported anywhere from 51% to 73% male
patients enrolled) [6,16–19,21–30,33–35,37,44,45]. However,
treatment recommendations are similar for male and female
patients.
Race
While MM is approximately twofold more common in blacks
(14.8 new cases per 100,000 males and 10.5 new cases per
100,000 females in the United States) than in whites (7.2 new cases
per 100,000 males and 4.3 new cases per 100,000 females) [14],
blacks are persistently underrepresented in clinical trials. For
example, in a phase III study examining vorinostat plus bortezomib
versus placebo plus bortezomib in relapsed patients who had
received 1–3 prior treatment regimens, 56.0% of patients were
white, while only 3.3% of patients were black; patients were
enrolled from 31 countries around the world [30]. Similar rates
were reported in two phase III studies examining lenalidomide
plus dexamethasone versus dexamethasone alone in relapsed
patients: the MM-009 study patient population was 82.1% white
and 11.9% black (enrolled from Europe, Israel, and Australia), while
the MM-010 study patient population was 98.3% white and 0.6%
black (enrolled from the United States and Canada) [46]. The phase
III study ASPIRE, which evaluated carﬁlzomib, lenalidomide, and
dexamethasone versus lenalidomide and dexamethasone in
patients with relapsed MM (1–3 prior regimens) from North
America, Europe, and the Middle East, also enrolled a patient pop-
ulation that was largely white (95.2%); 2.9% of patients were
black[34]. In the PX-171-004 study examining carﬁlzomib in
patients with relapsed MM from the United States and Canada,
among patients without prior bortezomib exposure, 76.0% of
patients were white and 14.0% of patients were black [21].
Interestingly, similar rates of enrollment have also been reported
in the ongoing real-world observational PREAMBLE study, which
is examining patients who have received one or more prior regi-
mens: 80.2% of enrolled patients are white and 16.2% are black
[16].
Evidence suggests that differences exist in the clinical features
of MM in blacks versus whites, such as differences in age at diag-
nosis, monoclonal immunoglobulin (Ig) concentrations, IgM iso-
type, and abnormal serum free light chain ratios [47–49].
Disease-speciﬁc survival has been reported to vary based on race,
but racial and socioeconomic disparities in treatment and outcome
may also play roles in these ﬁndings, as the use of transplantation
and novel agents also varies based on race and health insurance
[50,51]. Overall, adequately powered studies of ethnically diverse
populations are needed in MM to investigate biological differences
among different racial and ethnic groups in order to understand
whether treatment can be optimized for these patients.
High-risk disease
High-risk chromosomal abnormalities, such as deletion of
17p13 (del17p), or chromosomal translocations t(4;14), t(14;16),
and t(14;20) are associated with reduced response rates and
shorter survival times [52,53]. Among patients in clinical trials of
Table 1
Patient demographics and disease characteristics in key interventional clinical trials in relapsed MM.
Study/
reference
Patient population/treatment N Median age
(range)
Median time
since
diagnosis
Male sex ECOG PS ISS stage Cytogenetics b2-Microglobulin Renal impairment Prior therapy
[96] Relapsed from front-line anti-
MM treatment administered in
the HOVON-50 trial; treated in
daily practice
139 60 (34–69) 24.9 months
(range, 1.9–
61.4)
58% NR NR NR >2.7 lg/mL: 78% Median CrCl: 6 mmol/L NR
APEX [19] Relapsed MM (1–3 prior
therapies); treated with BTZ or
DEX
669 BTZ arm: 62
DEX arm: 61
BTZ:
3.5 years
DEX:
3.1 years
BTZ: 56%
DEX: 60%
NR NR NR BTZ: 3.7 mg/L
DEX: 3.6 mg/L
CrCl < 30 mL/min: 4.3%
30–50 mL/min: 15.6%
51–80 mL/min: 40.3%
<80 mL/min: 39.8%
1 prior: 38%
2–3 prior: 57%
CREST [20] Relapsed or refractory to ﬁrst-
line anti-MM treatment
regimen; treated with BTZ or
BTZ + DEX
54 63 2.0 years NR NR NR Abnormal
cytogenetics:
38%
P4 mg/L: 53% NR NR
NCT00813150
[38]
Relapsed and/or refractory MM
(1–3 prior therapies); treated
with
BTZ + DEX ± cyclophosphamide
96 71 (30–85) NR NR 0: 59%
1: 35%
2: 6%
NR NR NR NR 1 prior: 57%
2 prior: 30%
3 prior: 9%
[37] Relapsed or refractory MM (1–3
prior therapies); treated with
BTZ + DEX + cyclophosphamide
(induction) and
BTZ + cyclophosphamide
(maintenance)
59 69 (46–86) NR 56% 0: 65%
1: 29%
2: 5%
NR NR NR NR 1 prior: 75%
2 prior: 20%
3 prior: 5%
PX-171–004
[6,21]
Relapsed and/or refractory MM
(1–3 prior therapies; split into
groups with prior BTZ
treatment and with no prior BTZ
treatment); treated with CFZ
164 (prior BTZ:
35; no prior BTZ:
129)
Prior BTZ: 63
No prior BTZ: 65
Prior BTZ:
3.6 years
No prior
BTZ:
3.6 years
Prior BTZ:
51%
No prior
BTZ: 59%
Prior BTZ, 1
or 2: 54%
No prior
BTZ, 1 or 2:
60%
Prior
BTZ: II or
III: 43%
No prior
BTZ, I or
II, 73%
Prior BTZ:
high-risk
cytogenetics
26%
No prior BTZ:
unfavorable
cytogenetics
15%
Prior BTZ:
median 3.3 mg/L
No prior BTZ: NR
Prior BTZ:
CrCl < 50 mL/min 11%
No prior BTZ:
CrCl < 50 mL/min 16%
Prior BTZ:
median 3
No prior BTZ:
median 2
PX-171–006
[22,23]
Relapsed or progressive MM (1–
3 prior therapies); treated with
CFZ + LEN + DEX
84 61.5 3.1 years 57% In phase 2
dose-
expansion,
1 or 2: 61%
NR Unfavorable
cytogenetics:
26%
NR NR Median 2
ASPIRE [34] Relapsed MM (1–3 prior
therapies); treated with
CFZ + LEN + DEX
792 64.0 (31.0–91.0) 3.1 years 56% 0: 43%
1: 48%
2: 9%
I: 17%
II: 24%
III: 44%
High-risk
cytogenetics:
13%
<2.5 mg/L: 19%
P2.5 mg/L: 81%
CrCl < 30 mL/min:<1%
30–49 mL/min: 7%
50–79 mL/min: 41%
P80 mL/min: 51%
Median 2
1 prior: 43%
2–3 prior: 57%
NCT00558896
[24]
Relapsed/refractory MM (1–3
prior therapies); treated with
POM + DEX
60 65.5 3.7 years 60% NR II or III:
78%
Abnormal
cytogenetics:
33%
High-risk
FISH: 30%
3.5 lg/dL NR NR
NCT00908232
[26]
Relapsed/progressed MM (1
prior therapy); treated with
BTZ + DEX
163 64 (34–86) 2.6 years 53% NR NR NR NR GFR < 15 mL/min: 3%
15–29 mL/min: 10%
30–59 mL/min: 35.6%
P60 mL/min: 51%
NR
DOXIL-MMY-
3001 [33]
Relapsed or refractory MM (at
least 1 prior therapy); treated
with PLD + BTZ or BTZ
646 61 (28–88) 36.7 months 56% 0: 44%
1: 56%
NR Abnormal
cytogenetics:
18%
62.5 mg/L: 14%
>2.5 mg/L: 86%
Median serum
creatinine: 90.0 lmol/L
1 prior: 34%
P2 prior: 66%
MMVAR/IFM
2005–04
[18]
Relapsed or progressed MM
(ﬁrst relapse after at least 1
ASCT); treated with
BTZ + THAL + DEX or
THAL + DEX
269 61.2 (29–76) 3.1 years 63% NR I: 58%
II: 26%
III: 16%
Abnormal
cytogenetics:
41%
NR Median serum
creatinine: 79.6 lmol/L
NR
(continued on next page)
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Table 1 (continued)
Study/
reference
Patient population/treatment N Median age
(range)
Median time
since
diagnosis
Male sex ECOG PS ISS stage Cytogenetics b2-Microglobulin Renal impairment Prior therapy
MUK-Six [32] Relapsed and relapsed/
refractory MM (1–4 prior
therapies); treated with
PAN + BTZ + THAL + DEX
48 62 (41–76) NR NR NR I 54%
II: NR
III: 10%
NR NR NR Median 1
HOVON-86
[45]
First relapse or primary
refractory MM; treated with
BTZ + LEN + DEX (reinduction) +
LEN (maintenance)
77 66 (46–84) NR 64% NR I: NR
II: 26%
III: 5%
NR NR NR 1 prior: 100%
NCT00378209
[25]
Relapsed and refractory MM (1–
3 prior therapies); treated with
LEN + BTZ + DEX
64 65 (32–83) 2.8 years 66% NR NR Abnormal
cytogenetics:
27%
3.3 mg/L NR Median 2
MM-009 [28] Relapsed or refractory MM (P1
prior therapy) treated with
LEN + DEX or DEX
352
LEN + DEX: 176
DEX: 175
LEN + DEX: 63
(33–84)
DEX: 64 (40–82)
LEN + DEX:
3.4 years
DEX:
4.0 years
LEN + DEX:
59%
DEX: 58.9%
0: 41%
1: 43%
2: 14%
3:<1%
NR NR <2.5 mg/L: 28%
P2.5 mg/L: 72%
NR 1 prior: 32%
P2 prior: 68%
MM-010 [29] Progressive MM (P1 prior
therapy); treated with
LEN + DEX or DEX
353
LEN + DEX: 177
DEX: 176
LEN + DEX: 64
(36–86)
DEX: 62 (37–85)
LEN + DEX:
3.1 years
DEX:
3.1 years
LEN + DEX:
60%
DEX: 59%
0: 44%
1: 46%
2: 6%
NR NR LEN:<2.5 mg/L:
29%;P2.5 mg/L:
71%
DEX:<2.5 mg/L:
29%;P2.5 mg/L:
71%
NR 1 prior: 38.2%
P2 prior:
61.8%
NCT00773747
[30]
Non-refractory progressing MM
that had previously responded
to treatment (1–3 prior
regimens); treated with
VOR + BTZ or BTZ
637
VOR + BTZ: 317
BTZ: 320
VOR + BTZ: 61
(30–85)
BTZ: 63 (29–86)
62 years:
32%
>2 years:
68%
NR 0: 38%
1: 52%
2: 9%
3:<1%
I: 36%
II: 41%
III: 24%
NR 62.5 mg/L: 19%
>2.5 mg/L: 80%
NR VOR + BTZ:
median 2
BTZ: median 2
[54,55] Relapsed/refractory MM (64
prior therapies); treated with
BEN + BTZ + DEX
75 68 (41–85) NR 45% NR I-II: 74%
III: 27%
High-risk
cytogenetics:
22%
NR NR Median 1
1 prior: 53%
2 prior: 29%
3 prior: 8%
4 prior: 10%
NCT01701076
[44]
Relapsed/refractory MM (1 prior
therapy); treated with
BEN + LEN + DEX
50 68 (46–84) NR 73% NR II or III:
49%
High-risk
cytogenetics:
13%
NR NR 1 prior: 100%
PANORAMA-1
[27]
Relapsed or relapsed and
refractory MM (1–3 prior
regimens); treated with
PAN + BTZ + DEX or BTZ + DEX
768
PAN + BTZ + DEX:
387
BTZ + DEX: 381
PAN + BTZ + DEX:
63 (56–69)
BTZ + DEX: 63
(56–68)
NR 53.0% 0: 44%
1: 49%
2: 6%
I: 40%
II: 26%
III: 21%
NR NR CrCl 60–89 mL/min:
66.9%
P90 mL/min: 32.4%
1 prior: 51.4%
2 prior: 30.2%
3 prior: 18.1%
ASCT: autologous stem cell transplantation; BEN: bendamustine; BTZ: bortezomib; CFZ: carﬁlzomib; CrCl: creatinine clearance; DEX: dexamethasone; ECOG PS: Eastern Cooperative Oncology Group performance status; FISH:
ﬂuorescent in situ hybridization; GFR: glomerular ﬁltration rate; ISS, International Staging System; LEN: lenalidomide; MM: multiple myeloma; NR: not reported; PAN: panobinostat; PLD: pegylated liposomal doxorubicin; POM:
pomalidomide; THAL: thalidomide; VOR: vorinostat.
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Table 2
Patient demographics and disease characteristics in select observational studies in MM.
Study/
reference
Patient population N Median age
(range)
Time since
diagnosisa
Male
sex
ECOG
PS
ISS
stage
Cytogenetics b2-
Microglobulin
Renal
impairment
Prior
therapya
PREAMBLE
[16,90]
Relapsed or refractory
MM in real-world
daily practice
111 IMiD: 66 (43–
87) PI: 69 (37–
86) IMiD + PI:
67.5 (52–87)
IMiD:
3.6 years PI:
3.5 years
IMiD + PI:
2.8 years
52.3% NR I:
20%
II:
20%
III:
25%
High-risk
cytogenetics:
16%
NR NR 1 prior: 47%
2 prior: 30%
P3 prior:
22%
[17] Followed patients
with newly diagnosed
MM through relapse
at a single institution
578 65 NR 61% NR NR NR >2.7 lg/mL:
78%
Median
creatinine:
1.3 mg/dL
NR
ECOG PS: Eastern Cooperative Oncology Group performance status; IMiD: immunomodulatory agent; ISS: International Staging System; MM: multiple myeloma; NR: not
reported; PI: proteasome inhibitor.
aUpdated data presented at the 2014 Annual Meeting of the American Society for Hematology for 189 patients: time since diagnosis (all regimens), 41.0 months; 1 prior
therapy, 49%, 2 prior therapies, 32%.
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minority of patients, although it should be noted that many trials
also report a substantial number of patients with unknown cytoge-
netic status [6,18,20–25,34,54,55]. Different trials have utilized
varying deﬁnitions for the category of high-risk cytogenetics
[6,18,20–25,54]. Rates have ranged from 15% (for patients with
del17p, t(4;14), t(14;16), or hypoploidy) [21] to 30% (for patients
with del17 or del17p, t(4;14), or t(14;16)) [24], while abnormal
cytogenetics without deﬁnition of the speciﬁc aberrations were
reported in 41% of patients enrolled in a clinical trial examining
patients in their ﬁrst relapse [18]. The real-world observational
PREAMBLE study reported that 16% of patients had high-risk cyto-
genetics as deﬁned by ﬂuorescence in situ hybridization (FISH)
[16].
Beyond cytogenetics, other indicators of high-risk disease
include tumor burden and staging [56]. b2-Microglobulin is a
serum marker of tumor burden in patients with MM and has been
shown to be prognostic for patient survival [57–59]. The majority
of patients with relapsed MM in clinical trials have moderately
high levels of b2-microglobulin, typically above 2.5 mg/dL.
Median values of b2-microglobulin in trials in this setting have ran-
ged from 2.7 mg/L [15] to 3.7 mg/L [19], and 70–80% of patients
were reported to have b2-microglobulin >2.5 mg/L [28–30,34].
Serum b2-microglobulins and albumin form the basis of ISS
[50]. Between 31% and 78% of patients with relapsed MM who
are enrolled in clinical trials have ISS stage II or III disease at the
time of enrollment [6,18,24,25,27,30,34,44,45,60], and a somewhat
similar rate of ISS stage II or III disease was reported in the obser-
vational PREAMBLE study (45%) [16].
While ISS stage and high-risk cytogenetics are each prognostic
indicators in their own right, studies have shown that patients
with high-risk disease determined by a combination of ISS staging
(e.g. ISS stage II or III) and FISH (e.g. t(4;14) and/or del17p13) have
poorer prognoses than other patients, although these studies have
focused on newly diagnosed MM patients [61–63].
Patients with relapsed myeloma may present with elevated
serum lactate dehydrogenase (LDH) and/or extramedullary
involvement [64,65], features which indicate high-risk disease
[65,66]. Elevated LDH has been found to be an adverse prognostic
indicator for survival in patients with MM [67,68]. Extramedullary
disease is generally associated with poor outcomes [65], while
extramedullary relapses are associated with lower overall survival
and increased risk of bone plasmacytomas or fractures [64].
Treatment recommendations
As secondary genetic events are present in the relapse of mye-
loma, patients should be checked at the time of relapse for the
presence of del17p, at a minimum. This is an importantconsideration, as patients with relapsed myeloma and del17p
may beneﬁt from treatment with newer IMiDs (i.e. pomalidomide)
[69] or more aggressive procedures. Patients with t(4;14) may
beneﬁt from the use of proteasome inhibitor-based treatment
[70,71]. Patients with extramedullary disease may be candidates
for treatment with infusional chemotherapy with or without novel
agents (i.e. PACE, (V)DT-PACE, etc.) [72].
Renal impairment
Renal function is an important characteristic in patients with
MM, as the development of renal failure is a negative prognostic
factor for patient survival [73–75]. Renal dysfunction is a common
comorbidity in patients with MM, as excess monoclonal light chain
production associated with the disease often leads to kidney com-
plications. In the relapsed setting, the overproduction of the
involved free light chain may lead to cast nephropathy, which
may or may not be present at diagnosis. A number of patients
(5–15%) may present with ‘‘light chain escape’’ at relapse and thus
may develop renal impairment which was not present at diagnosis
[76]. Furthermore, amyloidosis may be another cause underlying
renal impairment, typically in patients at the late stage of their dis-
ease. In addition, a number of anti-MM agents are eliminated via
the kidneys (such as melphalan, prednisone, or lenalidomide),
necessitating careful selection of treatment regimens for patients
with renal impairment [77–81]. For this reason, clinical trials in
relapsed MM typically exclude patients with poor renal function
(e.g. creatinine clearance [CrCl] 6 30 mL/min).
In the MM-009 andMM-010 studies, 4.1% of patients had severe
(CrCl < 30 mL/min), 11.1% had moderate (30–49 mL/min), and
37.7% had mild renal impairment (50–79 mL/min); nearly half of
patients (47.1%) had normal renal function (P80 mL/min) [82].
Using similar deﬁnitions in the APEX study, which examined
patients with relapsed MM (1–3 prior therapies) receiving borte-
zomib versus dexamethasone, 4.3% of patients had severe renal
impairment, 15.6% had moderate impairment and 40.3% had mild
impairment; 39.8% of patients had normal renal function
(>80 mL/min) [83]. Similar results were reported in the ASPIRE
study, where 0.1% of patients had severe renal impairment, 7.1%
had moderate impairment, 40.9% had moderate impairment, and
more than half (51.0%) had normal renal function [34]. In a phase
II study in patients receiving bortezomib and dexamethasone as
second-line therapy with no eligibility restrictions based on renal
function, patients with severe or moderate renal impairment were
enrolled at slightly higher rates, although the investigators used
different cutoff values for reporting patient renal function: 12.9%
of patients had glomerular ﬁltration rate (GFR) < 30 mL/min,
35.6% had GFR 30–59 mL/min, and 50.9% had GFRP 60 mL/min
832 M.A. Dimopoulos et al. / Cancer Treatment Reviews 41 (2015) 827–835[26]. On the other end of the spectrum, in the PX-171-004 study,
severe or moderate renal impairment (CrCl < 50 mL/min) was
reported in only 11.4% of patients with prior bortezomib treatment
and 15.5% of patients who were bortezomib-naive [6,21].
Treatment recommendations
Patients with renal impairment should be treated with agents
that are excreted extrarenally, such as proteasome inhibitors
(bortezomib or carﬁlzomib) [84,85]. Dose adjustments may be
needed in patients with moderate or severe renal impairment
who are treated with agents predominantly excreted via the kid-
ney, such as lenalidomide [81]. Pomalidomide can also be used
in patients with relapsed MM [86].
Prior or existing peripheral neuropathy (PN)
PN is a common occurrence in patients with relapsed MM,
resulting from complications of the disease and treatment-
related toxicities. Patients who have previously received
thalidomide or bortezomib may have residual PN due to the prior
use of these drugs. Clinical trials in the relapsed setting often
exclude patients with severe PN at baseline. For example, the
PX-171-004, PX-171-006, and ASPIRE studies of carﬁlzomib
treatment in patients with relapsed MM required that enrolled
patients not have had PN that was grade 3 or 4, or grade 2 with
pain at baseline. Despite these restrictions, 53% of patients in
PX-171-004 and 36% of patients in ASPIRE had PN at baseline
[6,21], and 70–83% of patients in the PX-171-004 and
PX-171-006 studies had a history of PN [21,22]. The phase II study
NCT00558896 of pomalidomide plus low-dose dexamethasone in
relapsed or refractory patients also excluded patients with grade
3 or 4 PN, and 45% of enrolled patients had PN at baseline [24]. A
phase II study examining bortezomib as second-line treatment
(NCT00908232) excluded patients with grade 2 or higher PN, and
22% of patients had PN at baseline [26]. These ﬁndings illustrate
the prevalence of PN in the relapsed MM patient population, espe-
cially considering that PN-based exclusion criteria were used.
Treatment recommendations
As thalidomide or intravenous bortezomib have been associated
with the development of PN, patients with pre-existing PN should
be treated with other agents [87,88]. A phase III study has demon-
strated that subcutaneous bortezomib may be a suitable alterna-
tive as well, as it has been demonstrated to have reduced
neuropathy toxicity relative to intravenous administration [89].
Prior therapies received
The number and type of prior therapies received can have
important implications for patient treatment options and prog-
noses. Research has shown that the duration of patient responses
decreases with each successive regimen received, which is possibly
due to the development of therapeutic resistance [17]. As new
agents become available, the spectrum of regimens that patients
have been previously treated with evolves accordingly.
In a real-world observational study conducted between 1985
and 1998, of 578 patients followed from diagnosis, 0% received
thalidomide in their ﬁrst-line regimen, and only 7% received
thalidomide at any point during their treatment course [17]. In
contrast, latest data from 189 patients enrolled in the
multi-national observational study PREAMBLE, which was initiated
in 2012, show that IMiDs were administered as ﬁrst-line treatment
in 46% of patients (of whom 35% were from North America and 66%
were from Europe), and 46% of patients received proteasome inhi-
bitors ﬁrst-line (of whom 48% were from North America and 52%
were from Europe). Most patients receiving ﬁrst-line treatmentconsisting of an IMiD combined with a proteasome inhibitor
(n = 15) were from North America (80%) [90].
In clinical trials in which enrolled patients had received 1–3
prior regimens but which had no other restrictions on the types
of prior treatment patients could have received (i.e. the
PX-171-004, PX-171-006, and ASPIRE trials examining
carﬁlzomib-based regimens, and the NCT00558896 trial examining
pomalidomide-based treatment), between 21% and 77% of patients
had received prior bortezomib [6,23,24,34], and between 20% and
70% of patients had received prior lenalidomide [23,24,34]. These
large ranges may, in part, be indicative of the continuing evalua-
tion of how to best use these newer anti-MM agents. While not
reported in PX-171-004, rates of prior transplantation were similar
in the PX-171-006 and NCT0055896 trials (65% and 65%) and
slightly lower in the ASPIRE study (56%) [23,24,34]. Rates of prior
thalidomide were also similar in the PX-171-006 and
NCT00558896 trials (46% and 47%, respectively) [23,24].Treatment recommendations
The speciﬁc agents and classes of treatment patients have pre-
viously received are important considerations when evaluating
how to treat MM that has progressed. In patients with relapsed dis-
ease, re-treatment with agents from the initial regimen may be
considered in patients who achieved a partial response or better
and a remission lasting 12 months or longer following initial treat-
ment [91–94]. Patients who relapse rapidly following initial treat-
ment should receive a different class of agents from their original
treatment [95].Discussion
While some patient characteristics are similar across studies in
relapsed MM (such as sex or median age), others vary dramatically
from study to study (such as prevalence of high-risk disease or
renal impairment). These variations may originate from a number
of factors, the most predominant of which may be the speciﬁc clin-
ical questions being addressed in a given trial, including the treat-
ment regimen(s) that are being investigated. Trial enrollment
criteria can vary signiﬁcantly from trial to trial to select an appro-
priate patient population for investigation and can result in large
differences in patient demographics between trials. It should also
be noted that while some of the trials reviewed here focused on
patients with relapsed MM only, other trials included patients with
relapsed and/or refractory MM, which represents a patient popula-
tion more likely to have a poorer prognosis and/or baseline
comorbidities.
Observational studies tend to have less stringent eligibility cri-
teria than interventional clinical trials and so may be expected to
report a higher degree of heterogeneity across their enrolled
patient populations and thus be more similar to a real-world pop-
ulation. Unfortunately, there have been few observational studies
conducted in patients with relapsed MM, and those few have
reported limited information on patient demographics and disease
characteristics. Additional observational studies in relapsed MM
are needed to better understand how results from interventional
clinical trials may best be applied to diverse patient groups outside
a clinical trial setting.
Possessing greater knowledge of the demographic and baseline
disease characteristics of patients enrolled in clinical trials is
important for interpreting results and practically applying clinical
trial ﬁndings toward patient treatment. In this respect, data from
both clinical trials and real-world studies can inform individual
treatment decisions by providing an indication of how a particular
patient may beneﬁt from certain therapeutic approaches at each
stage of disease, while keeping in mind the level of response
M.A. Dimopoulos et al. / Cancer Treatment Reviews 41 (2015) 827–835 833achieved with previous treatment. While patients with relapsed
MM are a challenging patient population to treat, an awareness
of the individual patient’s unique clinical presentation can be valu-
able in helping to guide treatment choices to ultimately arrive at
the most beneﬁcial outcome for each patient.
Author contributions
All authors participated in the preparation of the manuscript
and contributed to initial drafts, edited version, and ﬁnal version.
All the authors read and approved the ﬁnal version before submis-
sion. M.A.D proposed the concept for the manuscript.
Conﬂict of interest statement
M.A.D. has served as a consultant for Celgene, Centocor Ortho
Biotech, and Onyx Pharmaceuticals. E.T. has received honoraria
from Onyx Pharmaceuticals, Janssen-Cilag, and Celgene, received
research funding from Janssen-Cilag, and served as an advisor for
Onyx Pharmaceuticals. R.N. has served as a consultant and received
research funding from Celgene, Millennium, and Onyx
Pharmaceuticals, and has served on speaker bureaus for Celgene,
Millennium, and Onyx Pharmaceuticals. A.P. has served as a con-
sultant or advisor for and received honoraria from Amgen,
Bristol-Myers Squibb, Celgene, Janssen, Millennium, and Onyx
Pharmaceuticals.
Acknowledgment
Medical writing support was provided by BlueMomentum, a
division of KnowledgePoint360 Group, an Ashﬁeld Company, and
funded by Onyx Pharmaceuticals, Inc., an Amgen subsidiary.
References
[1] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin
2013;63:11–30.
[2] Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al.
Continued improvement in survival in multiple myeloma: changes in early
mortality and outcomes in older patients. Leukemia 2014;28:1122–8.
[3] Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046–60.
[4] National Comprehensive Care Network. Clinical practice guidelines in
oncology. Multiple myeloma. Available from: <http://www.nccn.org>; 2015
[accessed February 2015].
[5] Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P, et al.
Clinically relevant end points and new drug approvals for myeloma. Leukemia
2008;22:231–9.
[6] Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, et al. An
open-label, single-arm, phase 2 study of single-agent carﬁlzomib in patients
with relapsed and/or refractory multiple myeloma who have been previously
treated with bortezomib. Br J Haematol 2012;158:739–48.
[7] Lonial S. Relapsed multiple myeloma. Hematol Am Soc Hematol Educ Program
2010:303–9.
[8] Ludwig H, Sonneveld P, Davies F, Blade J, Boccadoro M, Cavo M, et al. European
perspective on multiple myeloma treatment strategies in 2014. Oncologist
2014;19:829–44.
[9] Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R,
et al. International Myeloma Workshop Consensus. Consensus
recommendations for the uniform reporting of clinical trials: report of the
International MyelomaWorkshop Consensus Panel 1. Blood 2011;117:4691–5.
[10] Ludwig H, Durie BG, Bolejack V, Turesson I, Kyle RA, Blade J, et al. Myeloma in
patients younger than age 50 years presents with more favorable features and
shows better survival: an analysis of 10 549 patients from the International
Myeloma Working Group. Blood 2008;111:4039–47.
[11] Brenner H, Gondos A, Pulte D. Recent major improvement in long-term
survival of younger patients with multiple myeloma. Blood 2008;111:2521–6.
[12] Schaapveld M, Visser O, Siesling S, Schaar CG, Zweegman S, Vellenga E.
Improved survival among younger but not among older patients with Multiple
Myeloma in the Netherlands, a population-based study since 1989. Eur J
Cancer 2010;46:160–9.
[13] Palumbo A, Mina R. Management of older adults with multiple myeloma.
Blood Rev 2013;27:133–42.
[14] National Cancer Institute. SEER (Surveillance, Epidemiology and End Results)
Cancer Statistics Review, 1975–2010. Available from: <http://seer.cancer.gov/archive/csr/1975_2004/results_merged/sect_18_myeloma.pdf> [accessed
February 2015].
[15] Cook G, Williams CD, Cairns DA, Fletcher M, Cavenagh JD, Snowden JA, et al. A
second autologous stem cell transplant (ASCT2) induces superior durability of
response (DuR) following bortezomib-containing re-induction therapy for
relapsed multiple myeloma (MM): ﬁnal results from the BSBMT/UKMF
Myeloma X (Intensive) trial. Blood (ASH Annual Meeting Abstracts)
2013;122:765.
[16] Vij R, Moezi MM, Foà R, Cook G, Palumbo A, Kaya H, et al. A new multinational
observational study in multiple myeloma: initial report of the PREAMBLE
Study. Blood (ASH Annual Meeting Abstracts) 2013;122:1964.
[17] Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, et al.
Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc
2004;79:867–74.
[18] Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, et al.
Superiority of the triple combination of bortezomib-thalidomide-
dexamethasone over the dual combination of thalidomide-dexamethasone
in patients with multiple myeloma progressing or relapsing after autologous
transplantation: The MMVAR/IFM 2005–04 Randomized Phase III Trial from
the Chronic Leukemia Working Party of the European Group for Blood and
Marrow Transplantation. J Clin Oncol 2012;30:2475–82.
[19] Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T.
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N
Engl J Med 2005;352:2487–98.
[20] Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A
phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
Br J Haematol 2004;127:165–72.
[21] Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, et al. An open-
label, single-arm, phase 2 (PX-171-004) study of single-agent carﬁlzomib in
bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
Blood 2012;119:5661–70.
[22] Niesvizky R, Martin 3rd TG, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, et al.
Phase Ib dose-escalation study (PX-171-006) of carﬁlzomib, lenalidomide, and
low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin
Cancer Res 2013;19:2248–56.
[23] Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, et al. Phase
2 dose-expansion study (PX-171-006) of carﬁlzomib, lenalidomide, and low-
dose dexamethasone in relapsed or progressive multiple myeloma. Blood
2013;122:3122–8.
[24] Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, et al.
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for
relapsed multiple myeloma. J Clin Oncol 2009;27:5008–14.
[25] Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, et al. A
phase 2 trial of lenalidomide, bortezomib and dexamethasone in patients with
relapsed and relapsed/refractory myeloma. Blood 2014;123:1461–9.
[26] Dimopoulos MA, Beksac M, Benboubker L, Roddie H, Allietta N, Broer E, et al.
Phase II study of bortezomib-dexamethasone alone or with added
cyclophosphamide or lenalidomide for sub-optimal response as second-line
treatment for patients with multiple myeloma. Haematologica 2013;98:
1264–72.
[27] San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A,
et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus
bortezomib and dexamethasone in patients with relapsed or relapsed and
refractory multiple myeloma: a multicentre, randomised, double-blind phase
3 trial. Lancet Oncol 2014;15:1195–206.
[28] Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A.
Lenalidomide plus dexamethasone for relapsed or refractory multiple
myeloma. N Engl J Med 2007;357:2123–32.
[29] Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al.
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North
America. N Engl J Med 2007;357:2133–42.
[30] Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, et al. Vorinostat or
placebo in combination with bortezomib in patients with multiple myeloma
(VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol
2013;14:1129–40.
[31] Richardson PG, Jagannath S, Moreau P, Jakubowiak A, Raab MS, Facon T, et al.
Final results for the 1703 phase 1b/2 study of elotuzumab in combination with
lenalidomide and dexamethasone in patients with relapsed/refractory
multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2014;124:302.
[32] Popat R, Brown S, Flanagan LM, Cavenagh JD. Velcade, thalidomide,
dexamethasone and panobinostat (VTD-P) for patients with relapsed and
relapsed/refractory myeloma: preliminary results of the Muk-Six phase I/IIa
trial. Blood (ASH Annual Meeting Abstracts) 2014;124:4766.
[33] Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, et al.
Randomized phase III study of pegylated liposomal doxorubicin plus
bortezomib compared with bortezomib alone in relapsed or refractory
multiple myeloma: combination therapy improves time to progression. J
Clin Oncol 2007;25:3892–901.
[34] Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, et al.
Carﬁlzomib, lenalidomide, and dexamethasone for relapsed multiple
myeloma. New Engl J Med 2015;372:142–52.
[35] Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al.
Improved survival in multiple myeloma and the impact of novel therapies.
Blood 2008;111:2516–20.
[36] Corrado C, Santarelli MT, Pavlovsky S, Pizzolato M. Prognostic factors in
multiple myeloma: deﬁnition of risk groups in 410 previously untreated
834 M.A. Dimopoulos et al. / Cancer Treatment Reviews 41 (2015) 827–835patients: a Grupo Argentino de Tratamiento de la Leucemia Aguda study. J Clin
Oncol 1989;7:1839–44.
[37] Waal EGd, Munck Ld, Woolthuis G, Der AvV, Tromp Y, Hoogendoorn M, et al.
Combined treatment of bortezomib, continuous low-dose cyclophosphamide
and dexamethasone followed by one year of maintenance treatment for
refractory or relapsed multiple myeloma patients: a prospective phase II
study. Blood (ASH Annual Meeting Abstracts) 2014;124:4733.
[38] Kropff M, Vogel M, Kreter A, Schlag R, Müller L, Weide R, et al. Bortezomib and
low-dose dexamethasone with or without continuous low-dose oral
cyclophosphamide for primary refractory or relapsed multiple myeloma:
ﬁnal results of a national multicenter randomized controlled phase III study.
Blood (ASH Annual Meeting Abstracts) 2014;124:3470.
[39] Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blade J, Mateos MV.
Personalized therapy in multiple myeloma according to patient age and
vulnerability: a report of the European Myeloma Network (EMN). Blood
2011;118:4519–29.
[40] Lacrocca A, Bringhen S, Evangelista A, Ofﬁdani M, Ballanti S, Zaccaria A, et al. A
simple score, based on geriatric assessment, improves prediction of
survival, and risk of serious adverse events in elderly newly diagnosed
multiple myeloma patients. Blood (ASH Annual Meeting Abstracts) 2013;
122:687.
[41] Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al.
Geriatric assessment predicts survival and toxicities in elderly myeloma: an
International Myeloma Working Group report. Blood. Epub 2015 Jan 27. pii:
blood-2014-12-615187.
[42] Castelli R, Gualtierotti R, Oroﬁno N, Losurdo A, Gandolﬁ S, Cugno M. Current
and emerging treatment options for patients with relapsed myeloma. Clin Med
Insights Oncol 2013;7:209–19.
[43] Palumbo A, Gay F. How to treat elderly patients with multiple myeloma:
combination of therapy or sequencing. Hematol Am Soc Hematol Educ
Program 2009:566–77.
[44] Mey UJ, Brugger W, Bargetzi M, Schwarb H, Schwarzer A, Dechow T, et al.
Multicenter phase II trial of bendamustine, lenalidomide and dexamethasone
(BRd) as 2nd-line therapy for multiple myeloma. Blood (ASH Annual Meeting
Abstracts) 2014;124:4779.
[45] Broijl A, Kersten MJ, Alemayehu WG, Levin M-D, de Weerdt Okke, Vellenga E,
et al. Phase I/II trial of weekly escalated dose bortezomib combined with
lenalidomide and dexamethasone in patients in ﬁrst relapse or primary
refractory disease after ﬁrst line therapy for multiple myeloma. Blood (ASH
Annual Meeting Abstracts) 2014;124:4735.
[46] European Medicines Agency. European Medicines Agency Scientiﬁc
Discussion. Available from: <http://www.ema.europa.eu/docs/en_GB/
document_library/EPAR_-_Scientiﬁc_Discussion/human/000717/WC5000560
22.pdf>. [accessed February 2015].
[47] Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined
signiﬁcance and multiple myeloma in various ethnic/racial groups: support for
genetic factors in pathogenesis. Leukemia 2009;23:1691–7.
[48] Weiss BM, Minter A, Abadie J, Howard R, Ascencao J, Schechter GP, et al.
Patterns of monoclonal immunoglobulins and serum free light chains are
signiﬁcantly different in black compared to white monoclonal gammopathy of
undetermined signiﬁcance (MGUS) patients. Am J Hematol 2011;86:475–8.
[49] Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Weiss BM, Kristinsson SY, et al.
Racial disparities in incidence and outcome in multiple myeloma: a
population-based study. Blood 2010;116:5501–6.
[50] Warren JL, Harlan LC, Stevens J, Little RF, Abel GA. Multiple myeloma
treatment transformed: a population-based study of changes in initial
management approaches in the United States. J Clin Oncol 2013;31:1984–9.
[51] Joshua TV, Rizzo JD, Zhang MJ, Hari PN, Kurian S, Pasquini M, et al. Access to
hematopoietic stem cell transplantation: effect of race and sex. Cancer
2010;116:3469–76.
[52] Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al.
Genetic abnormalities and survival in multiple myeloma: the experience of the
Intergroupe Francophone du Myelome. Blood 2007;109:3489–95.
[53] Smith D, Stephenson C, Lach A, Chatters S, Kempski H, Yong KL. Cohort analysis
of FISH testing of CD138+ cells in relapsed multiple myeloma: implications for
prognosis and choice of therapy. Blood (ASH Annual Meeting Abstracts)
2014;124:3399.
[54] Ofﬁdani M, Corvatta L, Maracci L, Liberati AM, Ballanti S, Attolico I, et al.
Efﬁcacy and tolerability of bendamustine, bortezomib and dexamethasone in
patients with relapsed-refractory multiple myeloma: a phase II study. Blood
Cancer J 2013;3:e162.
[55] Ofﬁdani M, Maracci L, Corvatta L, Marina LA, Ballanti S, Attolico I, et al.
Bendamustine, bortezomib and dexamethasone (BVD) in patients with
relapsed-refractory multiple myeloma (MM): updated results of a
multicenter phase II study. Blood (ASH Annual Meeting Abstracts) 2014;124:
4734.
[56] Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, et al.
IMWG consensus on risk stratiﬁcation in multiple myeloma. Leukemia 2014;
28:269–77.
[57] Bataille R, Grenier J, Sany J. Beta-2-microglobulin in myeloma: optimal use for
staging, prognosis, and treatment – a prospective study of 160 patients. Blood
1984;63:468–76.
[58] Durie BG, Stock-Novack D, Salmon SE, Finley P, Beckord J, Crowley J, et al.
Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a
Southwest Oncology Group Study. Blood 1990;75:823–30.[59] Cuzick J, De Stavola BL, Cooper EH, Chapman C, MacLennan IC. Long-term
prognostic value of serum beta 2 microglobulin in myelomatosis. Br J
Haematol 1990;75:506–10.
[60] Orlowski RZ, Gercheva L, Williams C, Sutherland HJ, Robak T, Masszi T, et al.
Phase II, randomized, double blind, placebo-controlled study comparing
siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/
refractory multiple myeloma. J Clin Oncol (ASCO Annual Meeting Proceedings)
2012;30:8018.
[61] Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, et al. A novel
prognostic model in myeloma based on co-segregating adverse FISH lesions
and the ISS: analysis of patients treated in the MRC Myeloma IX trial.
Leukemia 2012;26:349–55.
[62] Avet-Loiseau H, Durie BG, Cavo M, Attal M, Gutierrez N, Haessler J, et al.
Combining ﬂuorescent in situ hybridization data with ISS staging improves
risk assessment in myeloma: an International Myeloma Working Group
collaborative project. Leukemia 2013;27:711–7.
[63] Neben K, Jauch A, Bertsch U, Heiss C, Hielscher T, Seckinger A, et al. Combining
information regarding chromosomal aberrations t(4;14) and del(17p13) with
the International Staging System classiﬁcation allows stratiﬁcation of
myeloma patients undergoing autologous stem cell transplantation.
Haematologica 2010;95:1150–7.
[64] Papanikolaou X, Repousis P, Tzenou T, Maltezas D, Kotsopoulou M, Megalakaki
K, et al. Incidence, clinical features, laboratory ﬁndings and outcome of
patients with multiple myeloma presenting with extramedullary relapse. Leuk
Lymphoma 2013;54:1459–64.
[65] Oriol A. Multiple myeloma with extramedullary disease. Adv Ther
2011;28(Suppl. 7):1–6.
[66] Zhuang J, Da Y, Li H, Han B, Wan X, Zhu T, et al. Cytogenetic and clinical risk
factors for assessment of ultra high-risk multiple myeloma. Leuk Res
2014;38:188–93.
[67] Kiba T, Ito T, Nakashima T, Okikawa Y, Kido M, Kimura A, et al. Bortezomib and
dexamethasone for multiple myeloma: higher AST and LDH levels associated
with a worse prognosis on overall survival. BMC Cancer 2014;14:462.
[68] Gkotzamanidou M, Kastritis E, Gavriatopoulou MR, Nikitas N, Gika D,
Mparmparousi D, et al. Increased serum lactate dehydrongenase should be
included among the variables that deﬁne very-high-risk multiple myeloma.
Clin Lymphoma Myeloma Leukemia 2011;11:409–13.
[69] Leleu X, Karlin L, Macro M, Hulin C, Garderet L, Roussel M, et al. Pomalidomide
plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or
translocation (4;14): IFM 2010–02. Blood 2015;125:1411–7.
[70] Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer
EA, et al. Bortezomib appears to overcome the poor prognosis conferred by
chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007;21:151–7.
[71] Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF. Improving
overall survival and overcoming adverse prognosis in the treatment of
cytogenetically high-risk multiple myeloma. Blood 2013;121:884–92.
[72] Srikanth M, Davies FE, Wu P, Jenner MW, Ethell ME, Potter MN, et al. Survival
and outcome of blastoid variant myeloma following treatment with the novel
thalidomide containing regime DT-PACE. Eur J Haematol 2008;81:432–6.
[73] Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma:
reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur
J Haematol 2000;65:175–81.
[74] Kleber M, Ihorst G, Deschler B, Jakob C, Liebisch P, Koch B, et al. Detection of
renal impairment as one speciﬁc comorbidity factor in multiple myeloma:
multicenter study in 198 consecutive patients. Eur J Haematol 2009;83:
519–27.
[75] Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early
mortality after diagnosis of multiple myeloma: analysis of patients entered
onto the United Kingdom Medical Research Council trials between 1980 and
2002 – Medical Research Council Adult Leukaemia Working Party. J Clin Oncol
2005;23:9219–26.
[76] Mead GP, Drayson MT. Sensitivity of serum free light chain measurement of
residual disease in multiple myeloma patients. Blood 2009;114:1717.
[77] Carlson K, Hjorth M, Knudsen LM. Toxicity in standard melphalan–prednisone
therapy among myeloma patients with renal failure – a retrospective analysis
and recommendations for dose adjustment. Br J Haematol 2005;128:631–5.
[78] Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S,
et al. Renal impairment in patients with multiple myeloma: a consensus
statement on behalf of the International MyelomaWorking Group. J Clin Oncol
2010;28:4976–84.
[79] Dimopoulos M, Alegre A, Stadtmauer EA, Goldschmidt H, Zonder JA, de Castro
CM, et al. The efﬁcacy and safety of lenalidomide plus dexamethasone in
relapsed and/or refractory multiple myeloma patients with impaired renal
function. Cancer 2010;116:3807–14.
[80] Niesvizky R, Naib T, Christos PJ, Jayabalan D, Furst JR, Jalbrzikowski J, et al.
Lenalidomide-induced myelosuppression is associated with renal dysfunction:
adverse events evaluation of treatment-naïve patients undergoing front-line
lenalidomide and dexamethasone therapy. Br J Haematol 2007;138:640–3.
[81] Celgene-Revlimid. REVLIMID Prescribing Information. Available from: <http://
www.revlimid.com/wp-content/uploads/2013/11/PI.pdf> [accessed February
2015].
[82] Weber DM, Spencer A, Wang M, Chen C, Attal M, Niesvizky R, et al. The efﬁcacy
and safety of lenalidomide plus dexamethasone in relapsed or refractory
multiple myeloma patients with impaired renal function. J Clin Oncol (ASCO
Annual Meeting Proceedings) 2008;26:8542.
M.A. Dimopoulos et al. / Cancer Treatment Reviews 41 (2015) 827–835 835[83] San-Miguel JF, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer
EA, et al. Efﬁcacy and safety of bortezomib in patients with renal impairment:
results from the APEX phase 3 study. Leukemia 2008;22:842–9.
[84] Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, et al. Carﬁlzomib in
multiple myeloma patients with renal impairment: pharmacokinetics and
safety. Leukemia 2013;27:1707–14.
[85] VELCADE (bortezomib) Prescribing Information. Cambridge, MA; Millenium
Pharmaceuticals, Inc. Available from: <http://www.velcade.com/Files/PDFs/
VELCADE_PRESCRIBING_INFORMATION.pdf>; 2014.
[86] Weisel K, Dimopoulos MA, Cavo M, Ocio EM, Palumbo A, Corradini P, et al.
Pomalidomide + low-dose dexamethasone in patients with refractory or
relapsed and refractory multiple myeloma and renal impairment: analysis of
patients from the phase 3b stratus trial (MM-010). Blood (ASH Annual Meeting
Abstracts) 2014;124:4755.
[87] Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau JL, Mohty M.
Peripheral neuropathy and new treatments for multiple myeloma:
background and practical recommendations. Haematologica 2010;95:311–9.
[88] Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O. Management
of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia
2012;26:595–608.
[89] Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, et al.
Subcutaneous versus intravenous administration of bortezomib in patients
with relapsed multiple myeloma: a randomised, phase 3, non-inferiority
study. Lancet Oncol 2011;12:431–40.[90] Vij R, Annemans L, Davis C, Le TK, Bartlett B, Moreau P. An ongoing
multinational observational study in multiple myeloma (PREAMBLE): initial
assessment of treatment patterns in patients with P6 months follow-up.
Blood (ASH Annual Meeting Abstracts) 2014;124:1297.
[91] Richardson P, Jagannath S, Colson K. Optimizing the efﬁcacy and safety of
bortezomib in relapsed multiple myeloma. Clin Adv Haematol Oncol
2006;4(Suppl. 13):1. discussion 8.
[92] Watanabe R, Tokuhira M, Kizaki M. Current approaches for the treatment of
multiple myeloma. Int J Hematol 2013;97:333–44.
[93] Conner TM, Doan QD, Walters IB, LeBlanc AL, Beveridge RA. An observational,
retrospective analysis of retreatment with bortezomib for multiple myeloma.
Clin Lymphoma Myeloma 2008;8:140–5.
[94] Madan S, Lacy MQ, Dispenzieri A, Gertz MA, Buadi F, Hayman SR, et al. Efﬁcacy
of retreatment with immunomodulatory drugs (IMiDs) in patients receiving
IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood 2011;
118:1763–5.
[95] Ludwig H, Beksac M, Blade J, Boccadoro M, Cavenagh J, Cavo M, et al. Current
multiple myeloma treatment strategies with novel agents: a European
perspective. Oncologist 2010;15:6–25.
[96] Gaultney JG, Franken MG, Tan SS, Redekop WK, Huijgens PC, Sonneveld P, et al.
Real-world health care costs of relapsed/refractory multiple myeloma during
the era of novel cancer agents. J Clin Pharm Ther 2013;38:41–7.
